BCL9L anticorps (N-Term)

N° du produit ABIN783409

Détail du produit anti-BCL9L anticorps

Antigène: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Épitope: N-Term

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BCL9L est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificité: This antibody detects Bcl-9-like protein at N-term. It is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist, this antibody will detect all four.

Réactivité croisée (Details): Species reactivity (tested):Human, mouse, rat

Purification: Affinity chromatography purified via peptide column

Immunogène: 20 amino acid peptide near the amino terminus of human Bcl9L

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: PBS containing 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2 - 8 °C for up to three months or (in aliquots) at -20 °C for longer.

Détails sur BCL9L

Antigène: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Autre désignation: Bcl-9-Like Protein (BCL9L Produits)

Synonymes: anticorps BCL9-2, anticorps DLNB11, anticorps B9L, anticorps BC003321, anticorps bcl9-2, anticorps BCL9L, anticorps B-cell CLL/lymphoma 9 like, anticorps B cell CLL/lymphoma 9-like, anticorps B-cell CLL/lymphoma 9-like, anticorps BCL9L, anticorps Bcl9l, anticorps bcl9l

Sujet: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with b-catenin, a target of the Wnt signaling pathway, and is required for enhanced ?-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating b-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.Synonyms: B-cell CLL/lymphoma 9-like protein, B-cell lymphoma 9-like protein, BCL9-like protein, BCL9L, DLNB11

ID gène: 283149

NCBI Accession: NP_872363

UniProt: Q86UU0

Pathways: Stem Cell Maintenance